Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, June 15, 2015

Acorda CEO Ron Cohen Named BIO Chairman for 2015-2016 Term

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, announced that President and Chief Executive Officer Ron Cohen, M.D, has been elected as the Chair of theBiotechnology Industry Organization (BIO) Board of Directors for the 2015-2016 term. He will also serve as the Chairman of the Health Section Governing Board.
“The biotech industry is among the most innovative in the world, developing life-changing medicines that improve our health, agricultural advances that help us feed an expanding global population, and cleaner, more efficient energy that allows us to fuel our economy while preserving our environment,” said Dr. Cohen. “It is a privilege to help BIO continue to advance our member companies’ collective mission to contribute these extraordinary advances to society.”
The BIO chair is a rotational position. Dr. Cohen will serve in this role through June 2016, and is eligible for re-election for another 1-year term. He previously served as Chair of the Emerging Companies Section Governing Board and Vice Chair of the Health Section Governing Board of BIO.
“Ron Cohen has been an active member of the Board for many years and will bring tremendous passion and a wealth of industry experience to help drive continued growth of BIO and the overall industry,” saidJim Greenwood, BIO President and CEO. “I look forward to working closely with Ron and our newly-constituted Board of Directors in the years to come.”
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.
Acorda markets three FDA-approved therapies, including AMPYRA®(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed. The Company has one of the leading pipelines in the industry of novel neurological therapies. Acorda is currently developing a number of clinical and preclinical stage therapies. This pipeline addresses a range of disorders including post-stroke walking deficits, Parkinson’s disease, epilepsy, neuropathic pain, heart failure, MS and spinal cord injury.

 Keep CURRENT with MS Views and NewsOPT-IN here


No comments: